Program: Oral and Poster Abstracts
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III
Several scores have been developed, such as the Sorror index, which allow to identify before transplant
subgroups of patients with different risks of death after allogeneic
transplantation (AloTH). One of the parameters included in all these scores and
routinely used in the pretransplant evaluation
include cardiac function studies. However, it has been heterogeneously defined
mainly based according to the ejection fraction using different approaches such
as MUGA and echocardiography. The aim of our study was to evaluate the
prognosis impact of pretransplant echocardiographic
findings.
We retrospectively analyzed a total of 276 medical records of patients
undergoing AloTH between 2006 and 2014. Additional data regarding demographic
parameters, underlying disease, donor type, conditioning, engraftment, acute
and chronic graft versus host disease, overall survival and cause of death were
also included into the analysis.
The mean ejection fraction was 61%, with 20 patients
displaying an ejection fraction <50%. 19 patients (7%) had diastolic
dysfunction, 5% valvular disease and 4% pericardial
effusion. Of the 19 patients with diastolic dysfunction, 57% had been treated
with anthracyclines: 7 patients (36%) were diagnosed
with acute leukemia and 4 (21%)patients with lymphoma.
In multivariate analysis we found that diastolic dysfunction was a predictor
for survival (HR 5.43, 95% CI: 0,08-20,2, p = 0.028)
and non-relapse mortality (HR = 5.7, 95% CI: 0,04-0,7, p = 0.002). Neither
ejection fraction nor any other echocardiographic parameter predicted the risk
of death.
In the present study pretransplant ejection fraction
did not influence the prognosis of patients undergoing allogeneic
transplantation; however, impaired diastolic function seems significantly
influences post-transplant mortality. Therefore, in the pretransplant
evaluation, diastolic function must be assessed in order to better define
patient risks. .
Disclosures: Falantes: Celgene: Honoraria .
See more of: Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence
See more of: Oral and Poster Abstracts
*signifies non-member of ASH